A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
NCT ID: NCT02399137
Last Updated: 2018-09-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
88 participants
INTERVENTIONAL
2015-05-31
2018-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT02101021
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
NCT02570711
Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
NCT02283372
Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
NCT01851174
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A (Experimental Arm)
MM-141 in combination with nab-paclitaxel and gemcitabine
MM-141
Gemcitabine
Nab-Paclitaxel
Arm B (Comparator Arm)
Placebo in combination with nab-paclitaxel and gemcitabine
Placebo
Gemcitabine
Nab-Paclitaxel
Observational Group
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MM-141
Placebo
Gemcitabine
Nab-Paclitaxel
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient must have received no prior radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease.
* Blood sample sent for free IGF-1 testing
* ECOG performance status (PS) of 0 or 1
Exclusion Criteria
* Patients with CNS malignancies (primary or metastatic)
* Clinically significant cardiac disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merrimack Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MM-141 Medical Director, MD
Role: STUDY_DIRECTOR
Merrimack Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner MD Anderson Cancer Ctr.
Gilbert, Arizona, United States
Pacific Cancer Medical Center, Inc.
Anaheim, California, United States
St. Jude Heritage Healthcare
Fullerton, California, United States
UCLA School of Medicine
Los Angeles, California, United States
Cancer Care Assoc Med Grp
Redondo Beach, California, United States
UCSF Cancer Center
San Francisco, California, United States
Sansum Clinic
Santa Barbara, California, United States
Central Coast Med Onc Corp
Santa Maria, California, United States
Rocky Mountain Cancer Centers
Aurora, Colorado, United States
Baptist Health Med Gr Onc, LLC
Miami, Florida, United States
Florida Cancer AffiliatesOcala
Ocala, Florida, United States
Memorial Regional Hospital
Pembroke Pines, Florida, United States
Cancer Treatment Centers of America-Georgia
Newnan, Georgia, United States
Northwestern University
Chicago, Illinois, United States
University of Illinois at Chicago
Chicago, Illinois, United States
Illinois Cancer Specialists
Chicago, Illinois, United States
Oncology Specialists, S.C.
Park Ridge, Illinois, United States
Midwest Regional Medical Cntr
Zion, Illinois, United States
Nylen Cancer Center
Sioux City, Iowa, United States
Cancer Center of Acadiana Research Department
Lafayette, Louisiana, United States
Reliant Medical Group, Inc.
Worcester, Massachusetts, United States
Compr Cancer Centers of Nevada
Henderson, Nevada, United States
New York Oncology HematologyPC
Albany, New York, United States
Roswell Park Cancer Inst
Buffalo, New York, United States
Bassett Cancer Institute
Cooperstown, New York, United States
North Shore Hematology Oncology Associates, PC
East Setauket, New York, United States
Columbia University Medical Center
New York, New York, United States
Columbia University
New York, New York, United States
Mid Ohio Onco/ Zangmeister Ctr
Columbus, Ohio, United States
Tulsa Cancer Institute, PLLC
Tulsa, Oklahoma, United States
St. Luke's University Health Network
Bethlehem, Pennsylvania, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Allegheny Cancer Center
Pittsburgh, Pennsylvania, United States
Vanderbilt-Ingram Cancer Ctr
Nashville, Tennessee, United States
SCRI - Tennessee Oncology
Nashville, Tennessee, United States
Texas Oncology-Austin Midtown
Austin, Texas, United States
Texas Oncology P A Bedford
Bedford, Texas, United States
Texas Oncology-Dallas P.H.
Dallas, Texas, United States
Brooke Army Medical Center (BAMC)
Fort Sam Houston, Texas, United States
Texas Oncology-Paris
Paris, Texas, United States
Texas Oncology-Plano East
Plano, Texas, United States
Texas Oncology SA Medical Ctr
San Antonio, Texas, United States
Texas Oncology-Tyler
Tyler, Texas, United States
Virginia Cancer Specialists PC
Fairfax, Virginia, United States
Onc and Hem Asso of SW VA Inc
Salem, Virginia, United States
Cancer Care Northwest, P.S.
Spokane Valley, Washington, United States
Northwest Cancer SpecialistsPC
Vancouver, Washington, United States
Cross Cancer Institute
Edmonton, Alberta, Canada
Klinikum rechts der Isar - TUM
München, Bavaria, Germany
Universitaetsklinikum Koeln
Cologne, North Rhine-Westphalia, Germany
Caritasklinik St. Theresia
Saarbrücken, Saarland, Germany
Vivantes Klinikum Neukoelln
Berlin, , Germany
Charite Universitaetsmd Berlin
Berlin, , Germany
Uniwersyteckie Centrum Kliniczne
Gdansk, , Poland
WSZ im. L. Rydygiera wToruniu
Torun, , Poland
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital General Universitario Gregorio Marañon
Madrid, , Spain
Centro Integral Oncologico Clara Campal
Madrid, , Spain
Hospital U de Fuenlabrada
Madrid, , Spain
Hospital Clinico Universitario de Valencia
Valencia, , Spain
Guy's Hospital
London, Greater London, United Kingdom
Sarah Cannon Research Institute UK
London, Greater London, United Kingdom
The Christie
Manchester, Greater Manchester, United Kingdom
Royal Marsden Hospital
Sutton, Surrey, United Kingdom
Royal Marsden Hospital
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kundranda M, Gracian AC, Zafar SF, Meiri E, Bendell J, Algul H, Rivera F, Ahn ER, Watkins D, Pelzer U, Charu V, Zalutskaya A, Kuesters G, Pipas JM, Santillana S, Askoxylakis V, Ko AH. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020 Jan;31(1):79-87. doi: 10.1016/j.annonc.2019.09.004.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MM-141-07-02-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.